Trials / Active Not Recruiting
Active Not RecruitingNCT04649385
BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Participants With Advanced Solid Tumors
A Phase 1 Study Investigating the Safety, Tolerability, Pharmacokinetics, and Preliminary Antitumor Activity of HPK1 Inhibitor BGB-15025 Alone and in Combination With Anti-PD-1 Monoclonal Antibody Tislelizumab in Patients With Advanced Solid Tumors
- Status
- Active Not Recruiting
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 157 (actual)
- Sponsor
- BeiGene · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The primary objective of this study is to assess the safety and tolerability of BGB-15025 alone and in combination with tislelizumab; and to determine the maximum tolerated dose (MTD) or maximum administered dose (MAD) and recommended Phase 2 doses (RP2D) of BGB-15025 alone and in combination with tislelizumab in participants with advanced solid tumors.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | BGB-15025 | Administered orally once or twice daily (QD or BID) |
| DRUG | Tislelizumab | Administered 200 mg intravenous (IV) infusion |
Timeline
- Start date
- 2021-03-04
- Primary completion
- 2025-10-17
- Completion
- 2026-05-16
- First posted
- 2020-12-02
- Last updated
- 2026-02-20
Locations
20 sites across 5 countries: United States, Australia, China, New Zealand, South Korea
Regulatory
- FDA-regulated drug study
Source: ClinicalTrials.gov record NCT04649385. Inclusion in this directory is not an endorsement.